Revisiting loxapine: A systematic review

Annals of General Psychiatry

Volumn 14, Issue 1, 2015, Pages

  Popovic, Dina ^a   Nuss, Philippe ^b,c   Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Agitation; Antipsychotic; Bipolar disorder; Loxapine; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LOXAPINE; PLACEBO;

AGGRESSION; AGITATION; BIPOLAR DISORDER; BIPOLAR MANIA; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSGEUSIA; HUMAN; LONG TERM CARE; MENTAL DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

EID: 84926667044     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/s12991-015-0053-3     Document Type: Review

References (102)

1. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry. 2001;9:89-104.
2. Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry. 2003;64 suppl 4:3-9.
3. Citrome L, Volavka J. The psychopharmacology of violence: making sensible decisions. CNS Spectr. 2014;26:1-8.
4. Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013;27(6):479-89.
5. Healy D. The creation of psychopharmacology. Massachusetts London, England: Harvard University Press Cambridge; 2004.
6. Delay J, Deniker P, Harl JM. Traitement des ètats d'excitation et d'agitation par une méthode médicamenteuse dérivè de l'hibernothèrapie. Ann Med Psychol. 1952;110:267-73.
7. Angst J, Bente D, Berner P, Heimann H, Helmchen H, Hippius H. Das klinische Wirkungsbild von Clozapin. Pharmakopsychiatrie. 1971;4:201-21.
8. Angst J, Jaenicke U, Padrutt A, Scharfetter C. Ergebnis eines Doppelblindversuches von HF 1854 im vergleich zu Levomepromazin. Pharmakopsychiatr Neuropsychopharmakol. 1971;4:192-200.
9. Allison L, Moncrieff J. 'Rapid tranquillisation': an historical perspective on its emergence in the context of the development of antipsychotic medications. Hist Psychiatry. 2014;25(1):57-69.
10. Scull A. Was insanity increasing? A response to Edward Hare. Brit J Psych. 1984;144:432-6.
11. Divry P, Bobon J, Collard J. Le R1625, nouvelle thérapeutique symptomatique de l'agitation psychomotrice. Acta Neurol Psychiatr Belg. 1958;58:878-88.
12. Schiele BC. Loxapine succinate: a controlled double-blind study in chronic schizophrenia. Dis Nerv Syst. 1975;36(7):361-4.
13. Mazzola CD, Miron S, Jenkins AJ. Loxapine intoxication: case report and literature review. J Anal Toxicol. 2000;24(7):638-41.
14. European Medicines Agency. Adasuve (loxapine) inhalation powder: EU summary of product characteristics; 2013. http://ec.europa.eu/health/documents/community-register/html/h823.htm (Accessed 22-Jan-2013)
15. Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997;154(11):1525-9.
16. Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry. 1999;60:52-60.
17. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry. 1999;60:31-41.
18. Glazer WM. Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry. 1999;60:42-6.
19. Lambert PA. Classification des neuroleptiques. In: Achaintre A, Balvet P, Beaujard M, Becache A, Berthier C, Broussolle P, editors. Actualities de therapeutique psychiatrique. Paris: Masson et Cie; 1963.
20. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10(4):515-31.
21. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl). 1995;120(3):365-8.
22. Chakrabarti A, Bagnall AM, Chue P, Fenton M, Palaniswamy V, Wong W, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev. 2007;4:CD001943.
23. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999;60:20-30.
24. Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania: a controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry. 1975;32:34-42.
25. Fruensgaard K, Wollenberg J, Hansen KM, Fensbo C, Sihm F. Loxapine versus perphenazine in psychotic patients: a doubleblind, randomized, multicenter trial. Curr Med Res Opin. 1978;5(8):601-7.
26. Simpson GM, Cuculic Z. A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients. J Clin Pharmacol. 1976;16:60-5.
27. Nordstrom K, Allen MH. Alternative delivery systems for agents to treat acute agitation: progress to date. Drugs. 2013;73(16):1783-92.
28. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-32.
29. Comai S, Tau M, Pavlovic Z, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol. 2012;32(2):237-60.
30. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183-92.
31. Belmaker RH. Bipolar disorder. N Engl J Med. 2004;351(5):476-86.
32. Keck PE, McElroy SL, Bennett JA. Pharmacologic loading in the treatment of acute mania. Bipolar Disord. 2000;2:42-6.
33. Goikolea JM, Colom F, Capapey J, Torres I, Valenti M, Grande I. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics: a meta-analysis of randomized clinical trials in acute mania. Eur Neuropsychopharmacol. 2013;23(4):305-16.
34. Goikolea JM, Colom F, Torres I, Capapey J, Valentí M, Undurraga J, et al. Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. J Affect Disord. 2013;144(3):191-8.
35. Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord. 2009;11 Suppl 2:45-54.
36. Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry. 1967;16:118-26.
37. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15:573-85.
38. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75-84.
39. Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol. 2010;24:547-58.
40. Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry. 2009;194:40-8.
41. Fountoulakis KN, Kasper S, Andreassen O, Blier P, Okasha A, Severus E, et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012;262 Suppl 1:1-48.
42. Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14:31-40.
43. Bourin M, Lambert O, Guitton B. Treatment of acute mania-from clinical trials to recommendations for clinical practice. Hum Psychopharmacol. 2005;20(1):15-26.
44. Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry. 1993;145:1455-6.
45. Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry. 1999;60 Suppl 5:43-7.
46. Fruensgaard K, Korsgaard S, Jorgensen H, Jensen K. Loxapine versus haloperidol parenterally in acute psychosis with agitation: a double-blind study. Acta Psychiatr Scand. 1977;56:256-64.
47. Moyano CZ. A double-blind comparison of loxitane loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients. Dis Nerv Syst. 1975;36:301-4.
48. Paprocki J, Versiani M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res Clin Exp. 1977;21:80-100.
49. Selman FB, McClure RF, Helwig H. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics. Curr Ther Res Clin Exp. 1976;19:645-52.
50. Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. J Clin Psychiatry. 1986;47:126-9.
51. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry. 1984;141(10):1195-202.
52. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;19(2):227-39.
53. Campbell M, Anderson LT, Small AM, Perry R, Green WH, Caplan R. The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord. 1982;12(2):167-75.
54. Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry. 1978;17(4):640-55.
55. Reinblatt SP, Abanilla PK, Jummani R, Coffey B. Loxapine treatment in an autistic child with aggressive behavior: therapeutic challenges. J Child Adolesc Psychopharmacol. 2006;16(5):639-43.
56. Craven-Thuss B, Nicolson R. Amoxapine treatment of interfering behaviors in autistic disorder. J Am Acad Child Adolesc Psychiatry. 2003;42(5):515-6.
57. Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51-8.
58. Allen MH, Feifel DA, Lesem MD, Zimbroff DL, Ross R, Spyker DA, et al. Efficacy and safety of loxapine for inhalation in the treatment of acute agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313-21.
59. Citrome L. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. Int J Clin Pract. 2011;65(3):330-40.
60. Spyker DA, Voloshko P, Heyman ER, Cassella JV. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J Clin Pharmacol. 2014;54(6):665-74.
61. Vanelle JM, Olie JP, Levy-Soussan P. New antipsychotics in schizophrenia: the French experience. Acta Psychiatr Scand, Supplementum. 1994;380:59-63.
62. Vieta E. The bipolar maze: a roadmap through translational psychopathology. Acta Psychiatr Scand. 2014;129(5):323-7.
63. Popovic D, Benabarre A, Crespo JM, Goikolea JM, González-Pinto A, Gutiérrez-Rojas L, et al. Risk factors for suicide in schizophrenia: systematic review and clinical recommendations. Acta Psych Scand. 2014;130(6):418-26.
64. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152:183-90.
65. Munro J, O'sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry. 1999;175:576-80.
66. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv. 1998;40:1029-33.
67. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology. 1997;8:671-7.
68. Meltzer HY, Alphs L, Green A, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91.
69. Bagadia VN, Shah LP, Abhyankar RR. A double-blind controlled trial of loxapine and trifluoperazine in adolescent schizophrenia. Curr Ther Res Clin Exp. 1980;27(6):886-96.
70. Bishop MP, Gallant DM. Loxapine: a controlled evaluation in chronic schizophrenic patients. Curr Ther Res Clin Exp. 1970;12(9):594-7.
71. Charalampous KD, Freemesser GF, Malev J, Ford K. Loxapine succinate: a controlled double blind study in schizophrenia. Curr Ther Res. 1974;6(8):829-37.
72. Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Dis Nerv Syst. 1972;33:783-91.
73. Clark ML, Paredes A, Costiloe JP, Wood F, Barrett A. Loxapine in newly admitted chronic schizophrenic patients. J Clin Pharmacol. 1975;15(4):286-94.
74. Clark ML, Paredes A, Costiloe JP, Fulkerson FG, Wood F. Evaluation of two dose levels of loxapine succinate in chronic schizophrenia. Dis Nerv Syst. 1977;38(1):7-10.
75. Du B-G, Fang R-L. Control studies on curative effects of loxapine succinate and risperidone in schizophrenics. J Clin Psychosomatic Dis. 2003;9(1):16-9.
76. Dube KC, Kumar N. Loxapine succinate: a comparative study with chlorpromazine. Curr Ther Res Clin Exp. 1976;19(6):653-60.
77. Dubin WR, Weiss KJ. Rapid tranquilization: a comparison of thiothixene with loxapine. J Clin Psychiatry. 1986;47(6):294-7.
78. Gallant B. Oxilapine versus trifluoperazine. Psychopharmacol Bull. 1971;7(1):40-3.
79. Huang S, Qin Y, Wang L. Study on the efficacy of loxapine in treatment of schizophrenia in comparison with chlorpromazine. Chinese New Drugs J. 1997;6(3):161-4.
80. Kiloh LG, Williams SE, Grant DA, Whetton PS. A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients. J Int Med Res. 1976;4(6):441-8.
81. Kramer MR, Thomas SPJ, Zorick FJ, Blackwell B. Relative efficacy and safety of loxapine succinate (Loxitane) and thioridazine hydrochloride (Mellaril) in the treatment of acute schizophrenia. Curr Ther Res. 1978;23(5):619-31.
82. Li Y, Shang J, Li C. Control study of loxapine succinate and clozapine on curative effects in treatment of schizophrenics. Heath Psychol J. 2004;12(3):202.
83. Li L-X, Li C-Y. A comparative study of loxapine succinate and risperidone in the treatment of schizophrenia. Shandong Arch Psychiatry. 2005;18(4):246-7.
84. Z-y L, Rui-fang HE. Comparative study between loxapine and risperedone in treatment of schizophrenia. J Clin Psychol Med. 2005;15(1):11-2.
85. Liu. Control study of loxapine and chlorpromazine in the treatment of schizophrenia. Med J ChinesePeople's Health. 2005;17(9):503-4.
86. Lu X-Q, Zhu G-L. Control studies of loxapine succinate and clozapine in treatment of schizophrenia. J Clin Psychosom Dis. 2003;9(3):157-8.
87. Malik SC, Kumar K. Loxapine in adolescent schizophrenia-a comparative study with trifluoperazine. Curr Ther Res Clin Exp. 1980;28(3):432-46.
88. Moore DF. Treatment of acute schizophrenia with loxapine succinate (Loxitane) in a controlled study with chlorpromazine. Curr Ther Res. 1975;18(1):172-80.
89. Pool D, Bloom W, Mielke DH, Roniger Jr JJ, Gallant DM. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res. 1976;19(1):99-104.
90. Rifkin A, Rieder E, Sarantakos S, Saraf K, Kane J. Isloxapine more effective than chlorpromazine in paranoid schizophrenia? Am J Psychiatr. 1984;141(11):1411-3.
91. Seth S, Mahal AS, Kumar KA. A double-blind comparative trial of loxapine and trifluperazine in chronic schizophrenic patients. Curr Ther Res. 1979;25(2):320-9.
92. Shopsin B, Pearson E, Gershon S, Collins P. A controlled double-blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients. Curr Ther Res Clin Exp. 1972;14(11):739-48.
93. Steinbook R, Goldstein BJ, Brauzer B, Moreno SS, Jacobson AF. Loxapine: a double blind comparison with chlorpromazine in acute schizophrenic patients. Curr Ther Res Clin Exp. 1973;15(1):1-7.
94. Tu Z-M, Gao S-R, Ye S-N. Controlled study of loxapineand chlorpromazine in the treatment of schizophrenia. Med J Chinese People's Health. 2004;16(7):415-7.
95. Tuason VB, Escobar JI, Garvey M, Schiele B. Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study. J Clin Psychiatry. 1984;45(4):158-63.
96. Van Der Velde CD, Kiltie H. Effectiveness of loxapine succinate in acute schizophrenia: a comparative study with thiothixene. Curr Ther Res. 1975;17(1):1-12.
97. Vyas BK, Kalla V. A six-month double-blind comparison of loxapine succinate and chlorpromazine in chronic schizophrenic patients. Curr Ther Res Clin Exp. 1980;28(1):16-30.
98. Wang L, Wang Z, Wang Y. Using loxapine succinate and chlorpromazine for treating schizophrenia. Tianjing Med J. 1996;24(11):672-5.
99. Wang. Control study of loxapine and quetiapine treating first onset schizophrenia. Chinese J Behav Med Sci. 2005;14(8):752.
100. Wang H-Y, Wang G-P, Pei G-X. A comparative study of loxapine and risperidone in the treatment of schizophrenic patients. Shandong Arch Psychiatry. 2005;18(1):28-9.
101. Xue S-J, Huang J-M, Yang M-Z. A comparison study on loxapine and chlorpromazine in the treatment of schizophrenia. Med J Chinese People's Health. 2004;16(10):593-4.
102. Zhang. Control study of loxapine treatment in schizophrenia. Sichuan Mental Health. 2005;18(4):222-4.